Renal Cell Carcinoma
Conditions
Keywords
Anesthesia, Propofol, Inhaled anesthetics, Renal cell carcinoma, Nephrectomy
Brief summary
This study investigates the influence of type of anesthesia on recurrence and survival of renal cell carcinoma in patients undergoing nephrectomy. The participants will be allocated to either the group receiving the total intravenous anesthesia (TIVA) using propofol or the group receiving the inhaled anesthetics, such as sevoflurane or desflurane.
Detailed description
The effect of anesthesia on cancer recurrence and survival is controversial. According to some retrospective studies and preclinical studies, TIVA is suggested to be more favorable than inhalation anesthesia regarding cancer recurrence and survival after surgery. However, to our knowledge, there is no study which investigates the influence of type of anesthesia on recurrence of renal cell carcinoma after nephrectomy.
Interventions
DRUGPropofol
Propofol 1-2 mg/kg bolus injection for induction of anesthesia propofol continuous infusion for maintenance of anesthesia
DRUGInhaled General Anesthetics
Sevoflurane or desflurane for induction and maintenance of anesthesia
Sponsors
Seoul National University Hospital
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Outcomes Assessor)
Intervention model description
A prospective randomized controlled study
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Adult patients scheduled for elective nephrectomy due to renal cell carcinoma
Exclusion criteria
* Emergency surgery * Pregnancy * Allergies to anesthetics * Palliative surgery * Refusal to participate in the study * History of diagnosis or surgery for other cancer
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| five year metastasis-free survival | five year after surgery | five year metastasis-free survival |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| three year metastasis-free survival | three years after surgery | three year metastasis-free survival |
| five year survival | five year after surgery | survival rate regardless of recurrence |
| one year survival | one year after surgery | survival rate regardless of recurrence |
| three year survival | three year after surgery | survival rate regardless of recurrence |
| one year metastasis-free survival | one years after surgery | one year metastasis-free survival |
Countries
South Korea
Outcome results
None listed